CXCL13 and lung adenocarcinoma: In conclusion, we propose further clinical investigations of CXCL13 as a predictive biomarker of ICI treatment in lung adenocarcinoma, which might reflect not only the functional status of cytotoxic T cells but also the tumor microenvironment represented by TLS.